文献速递心脏核医学

EXERRT试验:运动负荷不足后恢复期给予瑞加诺生对比未运动给予瑞加诺生的3b期开放标签平行组随机多中心研究,采用SPECT方案评估心肌灌注显像

The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol.
PubMed 文献 · J Nucl Cardiol · 2017-02-21

EXERRT为3b期开放标签平行组随机多中心研究,纳入运动负荷不足患者1147例,随机分为恢复期给予瑞加诺生0.4 mg组(Ex-Reg)与运动负荷不足1小时后给药组(Regadenoson),均行SPECT心肌灌注显像,主要分析两组可逆性灌注缺损节段分类的一致率。结果显示一致率差值的95%置信区间下限为-6%,高于-7.5%的非劣效界值,证明Ex-Reg对Regadenoson非劣效;Ex-Reg组不良事件数值上更少。结论认为在运动及恢复期无缺血症状体征的患者中,恢复期给予瑞加诺生可获得可比的可逆性灌注缺损节段分类,且在严密监测下似乎耐受良好。

要点

  • 恢复期给予瑞加诺生0.4 mg对无运动给药非劣效,一致率差值95%CI下限-6%高于-7.5%界值
  • Ex-Reg组不良事件数值上少于Regadenoson组(MPI1)
  • Ex-Reg组1例发生急性冠脉综合征、1例发生心肌梗死,给药前心电图已有缺血改变

核心结论

  • 恢复期给予瑞加诺生对可逆性灌注缺损节段的分类与非运动给药可比,在运动及恢复期无缺血症状体征的患者中严密监测下似乎耐受良好。

研究设计与样本

  • 3b期、开放标签、平行组、随机、多中心研究,共随机1147例运动负荷不足的患者。

主要发现

  • 一致率差值的95%置信区间下限为-6%,高于-7.5%的非劣效界值,证明Ex-Reg对Regadenoson非劣效。
  • 不良事件在Ex-Reg组(MPI1)数值上更少。
  • Ex-Reg组1例在运动后给予瑞加诺生后发生急性冠脉综合征,另1例发生心肌梗死,复核时两者在给予瑞加诺生之前已有符合缺血的心电图改变。

关键数值与推荐

  • 患者随机接受瑞加诺生0.4 mg,于恢复期给药(Ex-Reg)或运动负荷不足1小时后给药(Regadenoson)(MPI1)。
  • 所有患者还在1-14天后接受非运动瑞加诺生心肌灌注显像(MPI2)。
  • 主要分析评估Ex-Reg组与Regadenoson组之间多数一致率。

临床怎么用

  • 原文结论指出,对运动及恢复期无缺血症状体征的患者,恢复期给予瑞加诺生可获得可比的可逆性灌注缺损节段分类,并需严密监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study assessed the non-inferiority and safety of regadenoson administration during recovery from inadequate exercise compared with administration without exercise. METHODS: Patients unable to achieve adequate exercise stress were randomized to regadenoson 0.4 mg either during recovery (Ex-Reg) or 1 hour after inadequate exercise (Regadenoson) (MPI1). All patients also underwent non-exercise regadenoson MPI 1-14 days later (MPI2). The number of segments with reversible perfusion defects (RPDs) detected using single photon emission computerized tomography imaging was categorized. The primary analysis evaluated the majority agreement rate between Ex-Reg and Regadenoson groups. RESULTS: 1,147 patients were randomized. The lower bound of the 95% confidence interval of the difference in agreement rates (-6%) was above the -7.5% non-inferiority margin, demonstrating non-inferiority of Ex-Reg to Regadenoson. Adverse events were numerically less with Ex-Reg (MPI1). In the Ex-Reg group, one patient developed an acute coronary syndrome and another had a myocardial infarction following regadenoson after exercise. Upon review, both had electrocardiographic changes consistent with ischemia prior to regadenoson. CONCLUSIONS: Administering regadenoson during recovery from inadequate exercise results in comparable categorization of segments with RPDs and with careful monitoring appears to be well tolerated in patients without signs/symptoms of ischemia during exercise and recovery.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Thomas GS, Cullom SJ, Kitt TM, et al. The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol. J Nucl Cardiol. 2017. PMID: 28224449. doi:10.1007/s12350-017-0813-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。